 |
|
|
|
 |
|
|
| Article 1 to 4 out of 4 concerning Vasogen Inc.
|
-
Vasogen Announces Implementation of Strategic Restructuring Plan
(04/16/2008)
Vasogen Inc. announced that it has implemented a strategic restructuring plan to significantly reduce its cash burn rate and focus its efforts on opportunities that the Board and management believe are most likely to provide long-term shareholder ...
-
Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade in the European Union
(04/20/2007)
Vasogen Inc. announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), a European pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic heart failure in the ...
-
Vasogen Announces Results from Phase III SIMPADICO Trial in Peripheral Arterial Disease
(03/14/2006)
Study Did Not Meet Primary Endpoint
Vasogen Inc. announced the results from the 553-patient phase III SIMPADICO trial of its Celacade(TM) technology (Celacade) in peripheral arterial disease (PAD). While the SIMPADICO study did not reach the primary endpoint of change in maximal ...
-
Vasogen Announces the Appointments of Dr. Ronald Cresswell and Dr. Calvin Stiller to Board of Directors
(01/12/2006)
Vasogen Inc. announced that Ronald M. Cresswell, Ph.D., Hon. D. Sc., F.R.S.E., and Calvin R. Stiller, C.M., O.ONT, M.D., F.R.C.P.(C), have been named to its Board of Directors. Both Dr. Cresswell, former Senior Vice President and Chief Scientific ...
Additional information
Vasogen Inc.
Mississauga, ON, Canada
Company
|
|
|
|
|
|
Top
